Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?
Apimeds shares are surging Thursday after its subsidiary MindWave Innovations announced a technology services agreement with AQUAE Holdings.
Stocks · News reference
8-K filing — Apimeds Pharmaceuticals US, Inc. (APUS)
Filed: 2026-09-23 AccNo: 0001213900-26-102321 Size: 212 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
Apimeds Pharmaceuticals shares are trading higher after the company announced its subsidiary, MindWave, signed a 12-month technology services agreement with AQUAE Holdings to deploy its MindChain infrastructure as the foundation of AQUAEChain.
Apimeds Pharmaceuticals' MindWave Signs 12-Month Contract To Build Conservation Credit Platform For AQUAE, Plus 20% Credit Allocation